Back to search

Article

Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus

2022-12-20

Abstract excerpt

<h4>Background: </h4> Finerenone is a third-generation mineralocorticoid receptor antagonists, which has shown good cardiac function improvement in patients with type 2 diabetes in large-scale clinical trials. However, its specific role in diabetic cardiomyopathy remains unclear. We explored the potential functions and mechanisms of finerenone in diabetic cardiomyopathy. Methods After Sprague‐Dawley rats were indu...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ae32d1c4-2a29-5a36-9b14-20930a4263ab
DOI
10.21203/rs.3.rs-2372964/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitusDOI 10.21203/rs.3.rs-2372964/v1
Select a neighboring publication to make it the new centre.